Clinical Trial Update: Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Th1/Tc1 immunotherapy after stem cell transplantation in multiple myeloma; the study status is terminated with results posted in 2018…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Th1/Tc1 immunotherapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myeloma, Plasma-Cell, Myeloma-Multiple | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-10-16